TOGETHER. SHAPING THE FUTURE.

The Supreme Court has halted Sherley v Sebelius challenge to President Obama's March 2009 Executive Order of expanding government-funded research using embryonic stem cells. A federal judge in Washington in 2010 ordered the National Institutes of Health to halt funding of the research, citing a long-standing congressional ban on spending for research in which "human embryos are destroyed." But an appeals court overturned that order and ruled last year that the ban applied only to research which destroyed human embryos so as to obtain stem cells. President George W. Bush in 2001 had permitted research on several stem cell lines that were already in existence. President Obama went further and said NIH could conduct "scientifically worthy human stem cell research to the extent permitted by law." Under guidelines issued by NIH, researchers can use stem line cells derived from donated frozen embryos that are no longer needed for fertility treatments. Obama asked Congress to act and provide him legislation to sign into law after his 2009 Executive Order. However in a Democrat super majority in 2009/2010 with Republican support Congress as usual failed to act. The Diana DeGette (D-CO), and Michael Castle (R-DE) Stem Cell Research Act was never passed and languishes now in committee. According to mainstream perception, as Catholic I should be the last individual to support IVF donated HESC research or have a website dedicated to regenerative medicine investing. We as a free society make choices every day and my choice was to bring forth a dialogue based upon facts and not ideology. The court's action brings an end to a lawsuit based solely in an ideology with very little substantiated merits in reality. An unused IVF embryo for ethical medical research gives purpose to these cells that otherwise would be destroyed in a medical waste fire or similar. End of discussion. THANK YOU Supreme Court! I have seen the future and the future is regenerative medicine. The current healthcare model is bankrupting governments around the world and the medical technology is reaching maximum life prolonging possibilities. Mankind will not be able to take the quantum leap of the next evolutionary ladder unless the average aged is doubled. History repeats itself because those that remembered it are either dead, ill or no longer considered relevant. Investors have shouldered the financial burden of funding regenerative medicine company's clinical efforts for over a decade. I am confident that the Supreme Court's decision will open the flood gates to much needed equity investment across multiple channels in 2013 not only for HESC R&D, but for all cell types showing exciting possibilities. Cellular therapies have been saving lives for decades now in the form of bone marrow transplants. Other cellular therapies in clinical stage for regenerating eyes, tissue, hearts and variousneuro-degenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, often referred to as Lou Gehrig's Disease), Parkinson's disease (PD), and Multiple Sclerosis (MS) are showing incredible data. Many of these public entities are midway through a 20 year life cycle of clinical evolution with the FDA and incredibly undervalued. The data from these trials will lead to massive Big Pharma partnerships as Mesoblast saw in late 2010. I am calling the bottom on a majority of RegMed companies, beaten down since the collapse of the market in 2008 and continued private equity downturn. The science is catching up to the market now and is breaking through the dilution. Do you see the potential in these penny stocks? Ask yourself the following. How much would a treatment for the number one cause of blindness be worth? What is the value of a treatment that could regenerate a heart or stop Alzheimer's? Solving the riddle of cancer is said to be worth $60 trillion dollars. The upcoming growth in RegMed will make the Dotcom of the 90's seem miniscule in comparison. Below is just a few of the undervalued public companies were are following at http://investorstemcell.com/forum/forum.php

Originally Posted by Iarons

As many of you are aware, over the past couple of years, I’ve been tracking and reporting on the companies and institutions involved in research and clinical trials using both stem cells and gene therapy in ophthalmology. With the help of several industry sources, I have been able to put together the most comprehensive list of who is involved and what they are doing.

Because I have been updating this information almost on a daily basis, I’ve decided to no longer post the information on my online Journal (Irv Arons’ Journal), as it is out-of-date almost as soon as I post it. Therefore, I will only offer my tables of information to those who are interested in receiving them, and put notices on these forums when there is substantial new information to report.

Here is what is currently available:

Stem Cells

Stem Cell Companies (and Institutions) Active in Ophthalmology (Version 6, Jan. 27, 2012)

A list of seventeen companies and institutions working with stem cells for ophthalmic applications. The table lists collaborators, the cell type being used, and the applications against which the cells will be applied.

Stem Cell Therapy in Ophthalmology by Applications (Version 2, Jan. 20, 2012)

A list of seven ophthalmic applications being tested in clinical trials. The table includes which companies/institutions are involved, the clinical trial status, and the clinical trial number for those which are currently active. (Nine active clinical trials are listed, with live links.)


Gene Therapy

Gene Therapy Companies/Institutions Active in Ophthalmology (Version 10, Jan. 27, 2012)

The table lists more than twenty-five companies and institutions actively pursuing gene therapy solutions to ophthalmic diseases. The table shows the delivery viral platform, the gene type being used (where known), the application, and clinical status.

Gene Therapy in Ophthalmology by Application (Version 2, Jan.11, 2012)

This table, like the one for stem cells, lists the ophthalmic indication, the company/institutions involved, the clinical status, and the clinical trial number. (Fourteen active clinical trials are listed, with live links.)

Anyone interested in receiving a copy of any or all of the above tables, please contact me via email (iarons(at)erols.com) and let me know which ones, or all four, that you wish to obtain. The tables are in pdf format, and as mentioned, contain live links to all of the clinical trials listed.

(I will be out of the country, on vacation, for the next two weeks, so I apologize in advance if delivery of the tables is slow.)

Irv Arons

Originally Posted by Superfeeed

Just some thoughts as I continue to ponder the possible web options ( that are underway,) Yes I have been listening to what Members want, from web pages where iCELL members can reach their elected leaders in one click, to better rss feeds, to adding an editorial staff for original content publication and etc etc etc etc etc etc. Takes alot of money for a wish(s) to become a reality....

I am working with in a budget of my own personal financial support and thankful to those that have dug deep into his/her own pockets to support iCELL. The financial support freely donated by members since 4/2/2011 has made me continue on the journey of web development. Knowing that I am not alone and others believe in what we are trying to accomplish has made all the difference these many months. In addition to having MOD's and iCELL mgrs to keep order has made a big differnce as well.. Things take time to evolve. as an example THREE months after I thought www.stemcellceo.com would be ready, the files are now being updated again, the server migration corrupted them! Murphy's law coupled with a shoe string budget. People have said, well "charge" a membership fee "I dont mind paying $12.95 amonth"...a monthly membership fee would IMO limit access to a "Sector" that "Needs" all of the people it can collect. We All saw first hand this past week with Advanced Cell Technology the effect of an uninformed retail investor population trying to understand what the value and implications of a complicated science is to the market. RPE cells, engraftment, teratoma's, hESC, early indications, etc etc???,. A new investor with the average US 10th grade biology education must feel they need to go back to school after reading a RegMed press release!!? Many of you have been invested in some RegMed stocks for many months and or many years and yet we still need time to take it all in..Imagine being a newbie RegMed investor? iCELL needs to create a framework to get people up and running in a pleasing web environment...(working on it)..

Although the world does not know healthcare changed forever on 1/23/2012, an iCELL member knows it has. Validation comes in many forms does it not? From financial validation to knowing on 1/23/2012 that the past several years of watching ACT and other RegMed stocks has not been a waste of time...Last Monday ACT told us that the hRPE cells it had injected into the two cohorts in July 2011 were still alive, they had engrafted to the Bruch's membrane and they could track the hRPE cells visualy down to a cellular level to support these indications from the patients that they can see better. One of the trials cohorts said, “I just woke up one morning and looked through one eye and the other, and the difference was pretty dramatic,” she said. “I have an armoire across my room, and it has a lot of carved detail on it. I looked at it with the eye they operated on and could see all that detail. I just wanted to look at everything. It’s sort of like having new eyes.”
The cohort that said that was legally blind, damaged Bruch's membraine. What will happen with a treatment for early AMD? Complete restoration?

I know how discouraging it has been for some of you ACT investors to see your ACT shares go up and down like a roller coaster over the past several years along with the emotions that come with it. For what its worth I still have my big pile of ACT shares . I am still of the opinion that finding a treatment for AMD and 200 other eye disease is worth close to a trillion dollars in revenue in this decade alone for the Company that can show large scale efficacy. A 600 patient Phase 3 maybe needed? It may not mean much right now having 2 patients say it works along with perfect safety and digital imaging showing efficacy, but 24 patients? Now that is another thing.

No Idea can succeed except at the expense of endurance; having a hand in easing the suffering of millions is worth the pain of not knowing if we were right all along or just dreamers of a world where friends and family suffer no more. That is why I invest in RegMed, if I make a few bucks so be it.


Good luck...:tinfoilhat:

sf

Originally Posted by stockfodder

I can only speak for myself, the answer is Yes.
I can only guess for others, most likely Yes.
And sometimes I do worry about my investment, but it is one that I keep increasing my shares as information comes to us.

I looked on my Schwab acct today for outstanding shares and it read 1.71 billion. Not long ago it read around 1.56 billion. It is not something that I look at every day and Rocky's Corner has a running discussion and tracking of outstanding shares and who is getting the new settlement ones, as they get them. Visit Rocky's corner if you never have.

I can only speak for myself when I say that I look at this as a market cap investment. The question that I asked myself on day one two summers ago was: If ACTC can get into an FDA trial with its AMD stem cells, then where should it be if the trial results in a year or so (now running behind my first guess) begin to show efficacy, not just safety. My answer was this should be a 2-4 billion dollar company and growing. Divide the outstanding shares and I though we would be over a buck.
Now the investments premises have gotten a lot more complex and I won't tell anyone what they already know.

I believe tonight as I write this, with vision sounding like it has been achieved (and that information to be released in 4-8 weeks, my guess), and with a promised JV in China in the near future, what will be the market cap of that company.
My guess right now is in the 4 billion range before the end of 2012. Conveniently for me when I divide it out I am up there at one to two bucks per share.

For the investors just coming on the scene now, but getting up to speed, you lucky dogs...

I am underwater with this investment but feeling like we are on our way. A lot of shares hit the street this week, we had double avg sell days over 10MM and we may continue this.
Can't wait for concrete news and the end to all this speculation on the results. I believe the share activity per day will shoot right up and absorb the gifted shares. They will always have an impact, but at that point they will not stop the upward pps trajectory, just slow it for a while. imo.

It is hard sometimes for sure to forget about where you have placed your money when you have a week like this after a great beginning with Gary's blog. You have to go back and ask yourself, what where you thinking when you bought? What were the surprises since positive and negative? Do you still trust Lanza and Rabin, and the new additions to the team like Langer? Most importantly, do you still trust them... I do.

If you don't, then the question is... Well, it's the obvious question, as difficult as it might be.

I hope you all have a good weekend. I am going off to a Christmas party filled with ophthalmologists and eye technicians ( wife's company party). So much for getting from this investment! So far we are not on their radar screen! But I am hoping 12 months from now we will be....

After listening to the recorded version of the NIH meeting and hearing that waiting for Sherley matter to be resolved is the REASON for not moving forward on some endeavors is a perfect example of government CRATES that have never ever spent one minute employed by anyone other than the Federal Govt. I was sued 11 times when my business was expanding by those that did not like me taking business, NEVER stopped me from pushing forward on my business plan. Is it or is it NOT the Mission of the NIH to NIH’s mission is to seek fundamental knowledge about the nature and behavior of living systems and the application of that knowledge to enhance health, lengthen life, and reduce the burdens of illness and disability. Waiting TWO years to approve FOUR Stem Cell Lines from ACT that could not only provide a medical purpose to improve health for millions BUT also to CHANGE the discussion on "Embryo-Safe" and bring the ethical debate on hESC research to a logical end.. Man what a miss and an epic fail this. Not moving forward because we do not want to get sued? really shameful.

I would have to say that ACT going to China is genious for a JVP to get non-dilutive revenue is genious. The NIH and CIRM have turned its collective Backs on ACT @ this point.


CIRM approves $27 million for initiatives to accelerate promising stem cell research projects
CIRM approves $27 million for initiatives to accelerate promising stem cell research projects | Investor Stemcell

The External Innovation Initiative, which is part of the agency’s Opportunity Funds, allows CIRM to identify outstanding research taking place within the jurisdiction of any of the agency’s external collaboration network of funding partners. These partners, including 12 countries, two international states, one domestic state, two foundations, and most recently CIRM’s collaborative relationship with the National Institutes of Health, are available on the CIRM website

SOOOOOOOOOOOOOOOOOOOOOOOO, let me get this straight, So ACT is not considered promising research? the ONLY 2 FDA approved hESC human clinical trials is NOT considered "Promising".

If I was a resident of California I would ask the following to the CIRM and explain why 12 Countries are getting funds and not instate Corporations? The mission of CIRM is to support and advance stem cell research and regenerative medicine under the highest ethical and medical standards for the discovery and development of cures, therapies, diagnostics and research technologies to relieve human suffering from chronic disease and injury.


Ok so support Regenerative Medicine? I am not getting this mission. How does CIRM not have given ACT a $100,000 or $4,309,098?

I am amazed.

sf :furious:

Reality of being an Advanced Cell Technology Long Shareholder

My intention for building www.InvestorStemCell.com was to ensure that the flow of ALL information remained open. The PGG was a small place and we quickly out grew it. www.InvestorStemCell.com is growing and that is why I am building www.StemCellCEO.com it is needed for CEO's of StemCell Companies to engage its investor base and deliver information whilst maintaining brand, SEC mandates and utterly important to shareholders delivering information to the entire base in one swoop of the "send" buttom..... I am trying to imagine how many emails Mr. Rabin has received today from shareholders? 190? 249? 609? Blogging will save him and other CEO's an incredible amount of time as well as providing a platform that adheres to SEC requirements. IMO it will actually lessen the exposure to CEO's emailing shareholders individually..

I saw a genuine need for the niche for philanthropicapproach to life science investing in regenerative medicine in early 2010 with the PGG. Sure was great to see some much information and totaly new thought stages going on. I have learned a great deal from the experience.. Stem Cell Investors want to make money, secure great returns and also be apart of the evolution of RegMed science that may reshape healthcare as the world knows it. The demographic of Stem Cell Investors on iCELL is reflective of A to Z in our society. It is difficult to understand how the science of a particular company will translate its clinical science into a product worth investing in? I hope that iCELL has assisted many of you in gaining a better understanding of what it means to be a Stem Cell Investor.


Here is reality as I seen it today for ACT, the Company has 35,000(at least) individual shareholders. Of those IMO ACT has 20,000 longs that will never ever sell shares for the price of a ham sandwich.(myself being one of them) Unless ALL 35,000 ACT shareholders are coming to ACT-iCELL forums they know nothing of what is going on other than the price per share has dropped "again". Because iCELL has assembled the SMARTEST/Most Engaged retail stemcell investors in one place we sometimes forget that not everyone has found iCELL, Unfortunatly some people buy stock set a mental sell limit and a due date for expecting return and then shut it out, place it on a shelf and leave it be.

From previous volume averages it is appears that Midsummer Settlment is dumping 4-7million shares a day. They will be done on Thursday IMO. This reminds me exactly what happened with Bristol in 2010 Nov. The timing of it is well ironic in that the DSMB approval to continue towards the next cohorts is expected along with a 3 month clinical report due from ACT per FDA protocol in October. All midsummer cares about is getting that money out of those shares now IMO.. I was thinking today about Bristol in that two weeks after Bristol dumped 50million shares at 5 cents they could have sold those same shares at 25cents 3 weeks later LMAO.... IMO Midusmmer will feel the pain of "shouldawaited as they place its teepee next iwasgonna river".

For those angry about Mr. Rabin doing this and NOT doing that etc. I want to remind the longs that feel this way to keep in mind "FULL DISCLOSURE" The Company told shareholders the worst case scenario in an 8k last week. Would you rather NOT know? Would you rather have a CEO that flaps his hands against the keyboard and violates Section 12(a) with making false and misleading statements and subsequently the FDA halts the clinical for 20months? That would be REAL GREAT huh? Imagine the 100million blind people in the world suffering from MD? Real great for them?

I am thankful that ACT shareholders have a CEO that informs and returns emails, does not jeaparidize the Science/Company by "pumping" the science and trials of which could cause severe ramifications at the FDA and SEC level. Is he is perfect? Is anyone? yeah exactly.

Regardless everyone's opinion and comment matters. In times like this where shareholder anxiety is very high it is paramount to keep the flow of information and shareholder street feel going.

Right now the Doom and Gloom is heavy. ACT is a two sided coin, one side with a garbage capital structure and the other side of the ACT coin is a science that "may" possibly lead to a treatment for the 1# unmet medical need in the world. From the conversations I have had with eye Docs, injecting 50,000 healthy/perfect RPE cells is going to lead to something of clinical change in the condition when compared prior to the injections. What is that something? Will ACT's hRPE cells attack the drussen that has blocked the cones and rods? Will the cones and rods except nutrients from the RPE cells? Will the RPE latch onto the Bruch's membrane? None of them know for certain, just educated guess' on a technology that has never been used prior and thus why it is pennies. I place little merit on the market cap and or that ACT is trading at a market cap, nobody knows what the value is for a company that "may" have a treatment for the 1# unmet medical need in the world, but they sure as hell know the value of a company that carries 1.7Billion o/s and has alot of "what-ifs" pending. Only Clinical Validation will provide a true market cap.

Only ACT and UCLA know for certaintity today if the ACT hRPE cells are working.... Odd's are they know 100% right here and now/today. I say this because the Casey Paper indicated that maximum visual rescue occurred at Post Sixty days after injections. Did it work? I do not know. I do know that if it did not work the pps will not be 14cents as much as I know that if did work the pps will NOT be 14 cents! LOL. This is WHY the pps is 14 pps because investors do NOT know what the players are holding for cards!


sf

Disclosure: If investing in RegMed Clinical Stage Companies was easy everyone would be doing it. Removing the Drussen from a MD sufferer is validation if linked to visual rescue.

Originally Posted by rocky301

Mail,

The statement by Rabin that any significant revenues won't happen for "a couple of few years out"
and that most likely will be with Stargardt compassionate use, possibly in Europe is very much in line
with prior info I had posted in discussions with rumit and others. Below is an 8 month old post
using info available that puts the possible Stargardts Orphan program progress close to what Rabin is stating.
So no, not surprised at all.


__________________________________________________ __________________________________________________ __________

rumit,

Based on everything I have researched on orphan desiginated clinical trials I find the following to be a common denominator.

1)Time in clinical trials has increased the past few years

2)Amount of time to review/approve an NDA(new drug application) has been cut in half from 2 years to approx. 7 months-1 year.

Using the following chart link below(main article is second link) and you subtract out the IND time and NDA approval time it averages out to approx. 3 years in clinical phases.
Clinical Pharmacology & Therapeutics - Table 3 for article: Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000-2009

I have seen several sites with basically the same info. Most info mirrors the FDA stats "Approximately half of the approvals occurred by four years after being granted designation, and the most common patient population size was fewer than 10,000 patients"
Advanced Cell Technology (ACTC): 3 decent reads on Orphan Status/approval and off-label

So this suggests once again that AFTER you subtract out Orphan desig time(1 yr) and NDA approval time(7 months), clinical phases average around 2+ strong years..
So whether using FDA stats or mean chart stats, they are both in the same ballpark. I believe it falls more in line with Caldwells statement.."Typically, once a quadrant of patients is treated you will have 90 day, 6 months and one year data points"
Advanced Cell Technology (ACTC): rumit,Based on everything I have researched on orphan

As Americans anxiously await tonights speech from President Obama at 7pm EDT tonight on Jobs or should I say lack of jobs speech does the President realize this is truly his last chance? As one of the many independants that voted for and elected President Obama in 2008 I am not pleased with what I have seen for the most part. I understand he inherited a bad economy. I understand he inherited massive debt. I understand all this and I do not care any longer. I want results and I want people to stop with the sickening ideology rhetoric. (On both sides).

Big surprise in a recent CNN poll 74% of Americans agree with me.

If the President comes out tonight and blames anyone for anything he will be a one term President. If the President asks to borrow anymore money from Americans he will be a one term President. This is his most important speech tonight. Does he know this, does his "yes" woman/men surrounding him tell him this? I hope so. Because the more the country flounders, the more the push from zealots on the left for policy the harder the country will swing to the right. I am not talking Mitt Romney "right" of the wing of politics either.

Republicans and Democrats are equally at fault and only Republicans and Democrats together can solve this massive growing problem of debt and massive unemployment & underemployment in the United States.

So how do we do it? What really is causing this massive debt problem? Our trade policy with China is. Period.
But nobody at the white house, the republicans and or democrats talk about China being the main problem. As an example today, The Federal Bureau of Investigation agents on Thursday raided the headquarters of a California solar-panel maker that filed for bankruptcy this week and left U.S. taxpayers on the hook for as much as $527 million. The Chinese make the same product for 50% less than Solyndra can make it. How much longer will we stand by as China devaluates its currency by 7X causing every single solitary product to be cheaper than the US and or anyone else in the world can make them. Level the playing field I say. Match Tarrifs with Tarrifs. Next to the Germans, the American worker is the best worker. China is not shooting missles at us or trading bullets with the United States "yet". However they are conducting a campaign of weakening our countrys ability to protect ourselves. This is a 25 year assualt plan in my opinion. That they launched soon after Tiananmen Square in 1989.

If the President wants to blame anyone he needs to point the finger directly at China and for god sakes Mr. President do it now before it is too late. When we default China is not going to simply stand by and "say ok pay us when you can". No they are going to invade and take possession of Alaska etc.. Just think if we can increase revenue into the Federal Coffers we can have EVERY single solitary liberal wish list project. It comes down to revenue though. Increase revenue from Tarrifs on China. Bring our troops home through out the world and this debt problem will be fixed midway in your next term. Otherwise make the call to Jimmy Carter and tell him you will be filling his shoes for him on 2/21/2013.:furious:

Superfeeed

Originally Posted by catchall

Since i live in the northeast and see the wrath of nature first hand it is clear what kind of world it would be if a michelle or paul or other none trusting in the eventual goodness of government had the pen of law.
Even in this little company the possibilities of science overcoming disease are daily confronted by the nonebelievers of mankind being the "healing hand of the prime mover".
There are physical elements that come from the explosions of stars (elemental factories). They have intrinsic properties at temp and pressure and electric charge. They coalesce as the universal laws allow. The proteins formed respond to electrical charge and configure accordingly. Cells reproduce. Under an electric field they form different structures. Some of those cells should not reproduce for a duplication of the initial healthy organism. healthy organisms destroy the cancer cells routinely. Some basic laws of this science have been understood for only a decade or two. That is the way science evolves.
i just watched ALICE IN WONDERLAND..."OFF WITH THEIR HEADS SAYS THE EVIL QUEEN" the same solution to everything


a society of people with differences moves in fits and starts because "them that gots a lot now do not want change" and many of the wanters who by definition have less are just not bright enough to know what would truthfully benefit them yet sometimes it is different.
the government has to be behind (supportive) and infront of ( blocking the luddites) for this research to help people.
Last year $172,000,000,000 was spent on status quo medicine. Regenerative medicine can heal versus maintain disease is the hope and dream.

the worthwhile concept of nation is to improve the common situation ... thems that got a lot can also take care of themselves as they please after the common good is respected.

There are politicos out there who will try to stop this science ,,...,, so where do you stand? how will you express yourself?

Dear Members:
Changes at the CIRM this week may lead to expanding loans made to public companies. Jonathan Thomas, a founding partner of Saybrook Capital in Santa Monica, California, was elected by a 14-11 vote of the program's board. FCB-Pharmicell, a Korean pharmaceutical company, took a step closer to beginning commercial production of the world's first stem cell therapy as the Korea Food and Drug Administration said yesterday the approval will be given next week. Hearticellgram-AMI uses somatic stem cells extracted from the patient's own body. The bone marrow-derived mesenchymal stem cells will grow into heart tissue cells for regeneration of the patient's damaged heart. The medication is injected into the heart directly through a coronary artery. Lutheran pastor and theologian Dr. Ted Peters outlined the "moral framework" under which he supports stem cell research while speaking at the Christian Scholars' Conference at Pepperdine University last week. Peters argues that "everyone wants to do the right thing, based on their priorities or 'framework' of protecting embryos, furthering the discovery of regenerating healthy cells, or saving lives."
It is imperative as a culture we remove the stigmatism surrounding regenerative medicine. The costs surrounding healthcare are becoming unmanageable to the world economy as governments around the world realize they cannot afford promises given to its citizens in decades prior. Tough choices have to be made, both ethical and financial to ensure mankind continues to evolve. Regenerative medicine is the quantum leap the world desperately needs. Reducing the cost of healthcare, saving lives and easing the suffering of millions should not be a political bargaining chip or an ideological view any longer. Our community of early stage regenerative investors is playing a needed part and is just as fundamental as the other stakeholders in making commercialization of regenerative medicine a reality in this decade. Our passion for the science does not originate from simply wanting to make a few bucks. Many of us have endured personal loss from untreatable disease and so-called treatable disease. Since most of us can not quit our day jobs and go back to school to get Ph.D's in molecular science, we have chosen to do what we can and invest in a proven science. We are just as integral as any other stakeholder in regenerative medicine.
Please continue to reach out to your friends, family and community. Validation of regenerative medicine is upon the world. Advanced Cell Technology will bring photographic proof in October 2011 when the Company reports on its open label SMD/AMD cohorts. A picture of ACT's hRPE cells attaching to the Bruch's membrane will be worth much more than a thousand words.It will be validation. Members are encouraged to read over the Casey Eye Clinic study: http://www.advancedcell.com/our-technology/act-stem-cell-related-research-pipeline/
All of the subject rats were genetically engineered to go blind due to the die off of the RPE cells. In that study, those rats that received ACT's hRPE cell achieved 100% visual rescue over the non treated rats. If Mr. Lund is correct this will be a home run for humanity! Raymond Lund, Ph.D., a scientific collaborator with ACT, and considered one of the world's foremost experts in retinal cell physiology and vision restoration, commented, "The study results of ACT's RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run."

The ideologs on "both" sides of aisle have been playing political games in regards to hESC research for over a decade. Myself and millions of others whom have first hand experience with losing friends and family to untreatable disease are just completly fed up with politicians whom do not lead. It is a breath of fresh air to see US Sen. Mark Kirk (R-Ill.) leading on issue of such great importance.

Please contact Senator Kirk and applaud his efforts.

http://kirk.senate.gov/?p=contact&success=true

SF

Dear Members:



This week InvestorStemCell.com crossed the threshold of 1,000 Members! This milestone has been a community effort that continues to be a valuable resource for stakeholders of regenerative medicine.

Whether you want the latest news on your investment or educational facts on regenerative medicine it is becoming clear to many that InvestorStemCell.com is first-rate in its commitment to the sector.

Please continue to show your support for iCELL by being active in the community, donating a few dollars, discovering our ad sponsors, responding to erroneousness information put out on the web about regenerative medicine, or simply taking a few minutes to educate your friends & family about stem cell technology! It is up to "us" to protect stem cell technology. Our politicians have failed to lead once again. We must find common ground with those whom are naysayers. The time for name-calling or dismissing others opinion can no longer be the status quo! Engaging others in a respectful dialogue coupled with education is the only solution. If a pastor in Alabama takes it upon himself to educate a congregation on behalf of Geron Corp's brave young man "TJ" then so can't we? Check out this video of TJ's journey so far. http://abcnews.go.com/WNT/video/first-spinal-cord-surgery-stem-cells-13748702

Best

Superfeeed

Dear Members:



As we approach the 6 month passing of William "Bill" Caldwell IV former CEO of Advanced Cell Technology I wanted to acknowledge his contributions not only to ACT but the entire sector.

Mr. William M. Caldwell IV ("Bill") served as Chief Executive Officer of Advanced Cell Technology until his sudden death on December 13, 2010 at the age of 62. He received his B.A. degree from the University of Southern California and was a Multinational Enterprise Fellow at the Wharton School of Finance. His diverse global management background of almost 40 years made him the right person at the right the time to resurrect Advanced Cell Technology (OTC:ACTC) from the edge of bankruptcy in June 2008 to transforming ACT to the global leader in regenerative medicine in June 2011.

Thanks to Bill, interim CEO Gary Rabin, Dr. Robert Lanza and his team, Advanced Cell Technology is expected in June 2011 to begin a US Food and Drug Administration Phase I/II multicenter clinical trial using retinal cells derived from human embryonic Stem Cells (hESC) for both Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (AMD) the most common form of macular degeneration in the world affecting an estimated 150 million people. The trials will take place at UCLA's Jules Stein Eye Institute in California & Casey Eye Institute at Oregon Health & Science University in Portland, Oregon. No approved treatment is currently available for AMD, so an approved treatment is valued in the tens of billions of dollars.

Raymond Lund, Ph.D., a scientific collaborator with ACT and considered one of the world's foremost experts in retinal cell physiology and vision restoration, commented, "The study results of ACT's RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run."

Advanced Cell Technology pioneered a solution to the ethical, moral and legal debate surrounding human embryonic stem cell research. ACT has developed an "Embryo-Safe" technique. The "single-blastomere" technique awarded in February 2011, Patent Number 7,893,315 is a non-destructive alternative for deriving hESC lines. The single cell blastomere technology (SCB) uses a one-cell biopsy approach similar to pre-implantation genetic diagnosis (PGD), which is widely used in the in-vitro fertilization (IVF) process and does not interfere with the embryo's developmental potential. The safety record for one-cell biopsy as part of PGD now has a 15-year track record, and is carried out routinely as part of IVF processes around the world.

ACT's SCB technique can be paralleled in its use as a blood transfusion, but on a molecular level. In a traditional blood transfusion one pint yields trillions of red blood cells. ACT's "embryo-safe" technique extracts just one cell from two day old embryo. As the human body regenerates the billions of red blood cells removed, the two day old embryo also regenerates the one missing cell, making the human embryo as it was prior. ACT researchers have found that not only does the SC) technique solve the ethical concerns, but as an added benefit, the hESC extracted at such an early growth stage of the embryo are more robust and reproducible than traditional ICM derived lines. In a head-to-head comparison with 24 NIH lines, they are on average five times more efficient than the best NIH lines for producing cells from all three germ layers.

The legacy of Bill Caldwell can be measured in many ways. "To understand Bill you really need to look at him in three ways," said Dr. Robert Lanza, M.D., Chief Scientific Officer at ACT. "There was the businessman, the leader and the person. As a person, he was very humble and unassuming. As a leader, he created a culture where hard work and collaboration just came naturally. There is an incredible vibrancy to our company that Bill created. And as businessman, he was masterful. It is because he made it his mission in life that we are about to begin treating macular degeneration patients in the coming months, and have an exciting pipeline of new therapies of in the works. My greatest regret is that someday there will be people who will benefit from stem cell therapies, but who will never know the sacrifices that Bill and his wife Nancy made for their well-being".

The regenerative medicine community will be forever indebted to Mr. Caldwell for his visionary insight. Bill had several choices in ACT's pipe-line to move towards commercialization. He chose the "low hanging fruit" of ACT's RPE cells because of the tremendous animal trials. The old adage of a picture is worth a thousand words will come into play in that ACT's trial partners will image before and after the cohorts Bruchs membrane, of which will show the exact RPE layers before injections, after injections. It is my opinion that if the RPE cells adhere at a similar rate as the Casey Eye Clinica animal models did at Post 240 days Wall Street will tremble as investors flood to buy ACT. Those same investors however will waiting in line as Black-Rock and other institutional investors beat the MM's doors down.:cool:

IT IS THE SOLDIER

It is the Soldier, not the minister
Who has given us freedom of religion.
It is the Soldier, not the reporter
Who has given us freedom of the press.
It is the Soldier, not the poet
Who has given us freedom of speech.
It is the Soldier, not the campus organizer
Who has given us freedom to protest.
It is the Soldier, not the lawyer
Who has given us the right to a fair trial.
It is the Soldier, not the politician
Who has given us the right to vote.
It is the Soldier who salutes the flag,
Who serves beneath the flag,
And whose coffin is draped by the flag,
Who allows the protester to burn the flag.
©Copyright 1970, 2005 by Charles M. Province

Advanced Cell Technology OTC:ACTC & Geron Corp. NASDAQ:GERN

A David & Goliath comparison:

Regenerative medicine is a highly complicatedand vastly misunderstood science. Investor Stem Cell is dedicated to bringinginvestors and stakeholders together in thoughtful discussion to educate andpublicize the incredible advancements unfolding in the regenerative medicinesector.

A quantum leap in health care is upon theworld. Will you profit from thisemerging sector & help bring cures to millions? Find out now what the street thinks at www.investorstemcell.com

Side by side comparison of Advanced CellTechnology & Geron Corporation



Geron Corporation (NASDAQ:GERN), Approved by the FDAto use human embryonic stem cell (hESC)treatments to treat spinal cord injuries. Theresearch Goliath is a well-funded machine employing the top minds in the worldworking on everything from mid-stage oncologytrials to promising (hESC) drugs for spinal cord injuries, heart disease & cancer.

Snap shot of Goliath: Geron Corpoartion-(ASDAQ:GERN

· Seven oncology Phase 2trials currently underway, and has several big Pharma joint venture agreementsin oncology animal and human trials

· Five hESC areas ofinvestigation underway. GRNOPC1 is the lead candidate. Geron destroys thehuman embryo through its (hESC) R&D, of whichthe company uses the blastocyst embryo formation at day five afterfertilization from IVF clinics.

· Cash, restricted cash, cashequivalents and marketable securities: $221,274.000.00.

· Total operating expenses in 2010: $114,730,000.00.

· 175 employees; over 100hold PhD or MD degrees.

· Geron Corporation wasfounded in 1990 and is based in Menlo Park,California

· Trades on the NASDAQ providing liquidity & large institutional investors.

· Corporatefinancial statements: http://www.geron.com/investors/reports/GeronAnnualReport2010.pdf .



Advanced Cell Technology not too long ago was thepredominant leader in the field of regenerative medicine. It fell from that distinction in part due toexecutive management hubris and ultimately the credit crisis in mid-2008. ACT was able to resurrect itself from near bankruptcy in June 2008 and now has thedistinction of holding two out of the three FDA approved (hESC) trials. ACT is led by a competent executive managementteam and employs several of the most predominant regenerative researcher(s) inthe world.


Snap shot of David: Advanced Cell Technology-(OTC:ACTC)-

· Retinal Pigment EpithelialCell Program is their lead program-(HESC) trials for both SMD/AMD are expectedto start in week(s) Jules Stein EyeInstitute at the University of California, Los Angeles (UCLA ) will conduct the2 (hESC) trials for Stargardt’s Macular Dystrophy(SMD) and Dry Age-Related Macular Degeneration(AMD).

· Filed a European Clinical Trial Application for Phase 1/2 studyusing (hESC) to treat macular degeneration.

· Issued a broad patent for hESC-derived RPE cells in

· Seeking funding & jointventure partner for Myoblast program for the treatment of cardiovascular disease Phase 2 approved by the FDA.

· Joint ventured with Koreanmedical giant CHA to form “Stem Cell & Regenerative Medicine International”(SCRMI). This partnership expected to file an investigational new drug application with the FDA in Q-4 of this year. CHAbiotech is waiting for final approval from the KoreaFood and Drug Administration for (hESC) trial for AMD.

· Issued patent on its“single-blastomere” technique. Patent Number 7,893,315 broadly covers ACT’sproprietary single-blastomere technology that provides a non-destructivealternative for deriving hESC lines. This “Embryo-Safe” one-cell biopsyapproach similar to pre-implantation genetic diagnosis (PGD), which is widelyused in the in vitro fertilization (IVF) process and does not interfere withthe embryo’s developmental potential.

· 22 full-time employees, sixhold PhD or MD degrees-Formed in 1994, HQ in Menlo Park, California withlaboratory facilities in Marlborough, MA.

· Total operating expenses in2010: $22,044,701 .

· Cash, restricted cash, cashequivalents and marketable securities: $34,889,409 .

· Trades on the OTC:BB ACTC is a Sarbanes–Oxley Act SEC reporter.

· Corporate financialstatements: http://www.sec.gov/Archives/edgar/data/1140098/000101376211000631/form10k.htm



If you are looking for maximum possible ROIin the short term and can tolerate high risk, then maybe Advanced Cell Technology(OTC:ACTC) is for you? If ACT is validated by the FDA, the (RPE)MA-09 “embryo-safe” cell lines would open up an annual $25,000,000,000.00market treating (AMD). Yes that is (b) with an (illion) annual marketshare! No FDA approved treatment exist for (AMD) in the world. This disease effects 30 million in the USA& EU alone. Cell lines have potentialto treat 200 retinal eye diseases. ACT has been approved for U.S. Orphan Drug status protection for (SMD). This status by the FDA provides ACT sevenyears of market protection. ACT is expecting EU-Orphan Drug status for(SMD) and if awarded would receive 10-years of market protection. The recentpatent protection for ACT’s RPE cells in China firmly establish potential worlddominance of the (AMD) market. What is the down side? One glaringred flag is that ACT has two years of operating capitaland enough cash to fund both the SMD/AMD Phase-1/2 trials in theU.S. If ACT’s AMD/SMD trials are not validated, ACT would mostlikely be forced to institute a massive reverse split due to the O/S nearingits A/S .

ACT has placed all of its eggs in one pipelinebasket, choosing the low hanging fruit model. ACT is counting on theexceptional Casey Eye Clinic animal results. Dr. Raymond Lund Ph.D., considered one of theworld’s foremost experts in retinal cell physiologyand vision restoration. Dr. Lund recently said the following: “The studyresults of ACT’s RPE cells implanted in the various animalmodels of macular degeneration was phenomenal. If ACT observes even afraction of that benefit in humans, it will be nothing short of a homerun." .


Disclosure: www.investorstemcell.com is the world’s only online discussion forum dedicated bringing investors &stakeholders together in thoughtful discussion about stem cell &regenerative medicine. www.investorstemcell.com nor any of its Companies have beencompensated by “any” party for this article. Before making an investment decision an investor should perform duediligences. Once completed find out what the street thinks at www.investorstemcell.com .